Stockscreener 앱 받기
4.0901
0.85%
-0.0299
전일 마감가:
$4.12
열려 있는:
$4.15
하루 거래량:
373.63K
Relative Volume:
0.22
시가총액:
$513.09M
수익:
$44.55M
순이익/손실:
$-83.78M
주가수익비율:
-5.2613
EPS:
-0.7774
순현금흐름:
$-52.99M
1주 성능:
-0.12%
1개월 성능:
+0.12%
6개월 성능:
-34.32%
1년 성능:
+73.83%
1일 변동 폭
$4.08
$4.18
1주일 범위
$4.085
$4.29
52주 변동 폭
$2.375
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
명칭
Aquestive Therapeutics Inc
전화
908-941-1900
주소
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.09 | 516.85M | 44.55M | -83.78M | -52.99M | -0.7774 |
TAK
Takeda Pharmaceutical Co Adr
|
15.95 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.285 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.77 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.84 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
570.83 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 재개 | Oppenheimer | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | Raymond James | Outperform |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2019-04-22 | 개시 | H.C. Wainwright | Buy |
| 2019-01-03 | 개시 | Lake Street | Buy |
| 2018-08-20 | 개시 | JMP Securities | Mkt Outperform |
| 2018-08-20 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aquestive Therapeutics Inc 주식(AQST)의 최신 뉴스
AQST Stock Chart | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill
Aquestive Therapeutics Charts Cautious, Liquid Path Forward - TipRanks
Aquestive Therapeutics Q1 earnings call highlights - MSN
Aquestive Therapeutics CEO sells $35,413 in company stock By Investing.com - Investing.com South Africa
Aquestive Therapeutics CEO sells $35,413 in company stock - Investing.com UK
PRN_FinancialWrapper - FinancialContent
Aquestive secures $150 million debt facility with Oaktree By Investing.com - Investing.com Nigeria
Aquestive targets Q3 FDA resubmission for Anaphylm and projects >$150M cash at launch - MSN
A Quick Look at Today's Ratings for Aquestive Therapeutics(AQST.US), With a Forecast Between $6 to $9 - Moomoo
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Ardent Health Partners, Inc. (ARDT) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR) - The Globe and Mail
All News about Aquestive Therapeutics, Inc.Common Stock - The Chronicle-Journal
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Aquestive Says It’s on Track to Launch Anaphylm Studies for FDA - Allergic Living
Analysts Have Made A Financial Statement On Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) First-Quarter Report - Moomoo
The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2026 Earnings Call Transcript - Insider Monkey
Citizens reiterates Aquestive stock rating on Anaphylm progress By Investing.com - Investing.com South Africa
Citizens reiterates Aquestive stock rating on Anaphylm progress - Investing.com
Aquestive Therapeutics Signals Momentum In Earnings Call - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript Summary - Moomoo
Aquestive Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:AQST) 2026-05-14 - Seeking Alpha
Aquestive Therapeutics Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Aquestive’s Q1 2026 earnings beat forecasts, stock surges - Investing.com Nigeria
Aquestive Therapeutics Q1 2026 Earnings Call: Complete Transcript - Benzinga
Aquestive Therapeutics (AQST) reports Q1 loss, beats revenue estimates - MSN
Compared to estimates, Aquestive Therapeutics (AQST) Q1 earnings: A look at key metrics - MSN
AQST Achieves Strong Q1 Revenue and FDA Progress - GuruFocus
Aquestive Therapeutics earnings beat by $0.06, revenue topped estimates - Investing.com Canada
AQST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Aquestive Therapeutics Incenters five-year term loan facility of up to $150 million on May 12, 2026SEC filing - marketscreener.com
Aquestive Secures New Oaktree Term Loan to Fund Anaphylm - TipRanks
Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's After-Market SessionAquestive Therapeutics (NASDAQ:AQST) - Benzinga
Aquestive Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Investing News Network
Aquestive Therapeutics: Q1 Earnings Snapshot - KTVB
Aquestive Therapeutics (AQST) trims Q1 loss and secures $150M Oaktree debt facility - Stock Titan
BRIEF-Aquestive Therapeutics, Inc. Q1 Revenue USD 14.446 Million Vs. IBES Estimate USD 10.9 Million - TradingView
Aquestive Therapeutics, Inc. Reaffirm Earnings Guidance for the Full Year 2026 - marketscreener.com
Aquestive Therapeutics Signs New $150 Million Debt Facility - Moomoo
Aquestive Therapeutics Secures $150M Refinancing Deal Ahead of Potential Anaphylm Launch - citybiz
Aquestive Therapeutics sees $150M debt refinancing - ROI-NJ
Aquestive secures $150 million debt facility with Oaktree - Investing.com UK
Aquestive Therapeutics Announces $150 Million Debt Refinancing to Support Anaphylm™ Launch if Approved by FDA - Quiver Quantitative
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree - The Manila Times
Aquestive Therapeutics Inc (AQST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
1.89%
자본화:
|
볼륨(24시간):